Lundbeck acquires phase I-ready candidate from South Korean firm

Lundbeck has gained exclusive rights to biotherapy candidate APB-A1 from Aprilbio. The deal may cost up to USD 448m, and Lundbeck sees potential for the drug in several neurological indications.
Photo: Jens Dresling
Photo: Jens Dresling
by Elizabeth Mønsted-johansen, translated by catherine brett

Danish pharmaceutical giant Lundbeck has acquired exclusive rights to a biotherapy candidate for treating neurological diseases from Aprilbio, in a deal that may cost up to USD 448m.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
!
!
Must contain at least 6 characters
!
Must contain at least 2 characters
!
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

!
Newsletter terms

Front page now

Further reading